GS-829845

GS-829845 is a major, active metabolite of Filgotinib (HY-18300) . GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life[1][2].

Product Specifications

CAS Number

[1257705-09-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite; JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/gs-829845.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S1(CCN(CC1)CC2=CC=C(C3=CC=CC4=NC(N)=NN43)C=C2)=O

Molecular Formula

C17H19N5O2S

Molecular Weight

357.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Amy Meng, et al. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies. Br J Clin Pharmacol. 2022 Jul;88 (7) :3211-3221.|[2]Chia-Hsiang Hsueh, et al. Evaluation of the potential drug interactions mediated through P-gp, OCT2, and MATE1/2K with filgotinib in healthy subjects. Clin Transl Sci. 2022 Feb;15 (2) :361-370.